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Abstract: Chronic kidney disease (CKD) patients are at an increased risk of cardiovascular complications and plasma 
leptin level is elevated in cardio renal syndrome. We wanted to explore leptin levels in patients with different stages of 
CKD and find its association with risk of cardiovascular disease. This cross-sectional study was conducted in 
Nephrology Department of Jinnah Post Graduate Medical Centre (JPMC) from January 2014 to September 2014. Group 
I comprised of controls (GFR=116±8.3, n = 44) acquired from general population, CKD patients were grouped as II, III 
and IV respectively with GFR; 85.77±9.9 (n = 42), 53.84±9.9 (n=42) and 20.22±8.4 (n = 42).CKD patients with any 
inflammatory disease, Diabetes Mellitus and on steroid therapy were excluded. Serum leptin, lipid profile and C reactive 
proteins (CRP) were measured. Leptin and CRP levels increased significantly with progression of CKD. High density 
lipoproteins (HDL) to low density lipoproteins (LDL) ratio was significantly high in control as compared to CKD groups 
(p<0.001). A positive correlation of leptin was observed with CRP and HDL/LDL ratio (r= 0.994,p<0.001 and r= 
-0.403p<0.001) respectively. Hyperleptinemia observed with progression of CKD contributed to pathogenesis of 
cardiovascular disease by decreasing HDL/LDL ratio. 
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INTRODUCTION 
 
End-stage renal disease (ESRD) is a complication of 
impaired renal function and chronic kidney disease 
(CKD) associated with increased morbidity, mortality, and 
increases the risk of cardiac disease (CVD).The 
prevalence of CKD is high in Pakistani population, since 
incidence of hypertension and diabetes in our inhabitants 
is one of the highest in the world. 
 
CKD is linked to a series of multiple toxic physiological 
and metabolic functions. Diabetes and hypertension as 
being its complication are concomitant with lethal 
outcomes. An increased risk of CVD in these patients can 
lead to mortality(Locatelli et al., 2003) which is attributed 
to inflammatory and oxidative stress, erythropoietin(EPO) 
resistance leading to anemia(Kazory and Ross 2009), 
vitamin D deficiency (Levin and Li 2005) and vascular 
calcification (Mizobuchi et al., 2009). Adipocytokines 
such as leptin, are also potentially involved in the 
pathogenesis of metabolic syndrome (e.g. dyslipidemia) 
in End-stage renal disease (Mak and Cheung 2007). 
 
Leptin is an adipose tissue-derived hormone that has been 
associated to numerous metabolic and inflammatory 
factors involved in the pathogenesis of hypertension and 
cardiovascular disease (Wannamethee et al., 2007). 
Increased leptin levels are in response to high energy 
deposition in the form of adipocytes and obesity, 
irrespective of the degree of BMI (Fatima et al., 2013).In 
renal disease the scenario is much different, as the 
initially CKD may be altered with change in grades of 
obesity; and therefore increasing leptin levels and 
resistance (fig. 1). Hyperleptinemia is observed in patients 
during CKD progression and potentially anorexic-
cachectic syndrome. However, histological changes in the 
basement membrane from initial to end stage disease may 
also contribute to the decreased levels of leptin at the end 
stage of CKD (Becker et al., 2005). Leptin is known to be 
important in the regulation of food desire, body 
composition and might also be responsible for metabolic 
changes during CKD leading to inflammation and loss of 
lean body mass (Mak et al., 2006). 
 
[SF1] 
Fig. 1: This diagram shows the illustration of the 
hypothetical mechanism of etiology of Chronic Kidney 
Disease. 
 
The etiology of kidney dysfunction may initially be 
associated with long-standing obesity and insulin 
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resistance, like the metabolic syndrome (MetS). Leptin is 
predominantly washed out from the circulation by the 
kidneys after the metabolic degradation in the renal 
tubules (Cumin et al., 1996). Shamsuzzaman et al. 
(Shamsuzzaman et al., 2004) established an association 
between serum levels of leptin and C-reactive protein 
(CRP) in healthy young adults. Leptin plays a role in 
stimulating the sympathetic system of the body leading to 
elevated blood pressure and deranged GFR(Carlyle et al., 
2002 including natriuresis (Jackson and Li 1997)to 
maintain the electrolyte homeostasis (Hall et al., 1990). 
The reduced clearance of plasma leptin leads to high 
levels of circulating leptin probably due to feedback-loop 
that down regulates certain genes in hyperleptinemic 
patients having advanced CKD (Nordfors et al., 1998).  
 
Increased adiposity (measured in reference to BMI) is 
associated with increased serum leptin levels as it is 
recognized to proportional to obesity. The oxidative stress 
caused by the activation of reactive oxygen specie (ROS) 
during the sub clinical inflammatory condition during 
obesity, leads to the damage of the podocytes thus leading 
to advanced CKD (Sharma et al., 2008). 
 
The objective of the study was to explore leptin levels in 
patients with different stages of ESRD and find its 
association with metabolic dysfunction in CKD patients. 
With the agreement that obesity and hyperleptinemia both 
cause metabolic dysfunction in CKD patients, we selected 
patients with normal BMI and then studied the 
relationship of Leptin, inflammatory marker reactive 
protein and metabolic dysfunction in CKD patients. 
 
MATERIALS AND METHODS 
 
Study participants 
This cross-sectional study was conducted in the 
Department of Biological and Biomedical Sciences 
(BBS), Aga Khan University in collaboration with the 
Nephrology Department of J.P.M.C. during the period of 
January 2014 to September 2014. Two hundred patients 
were recruited for the study out of which 170 subjects 
were enrolled in present study. CKD patients between the 
ages 35- 45 years without any known cardiovascular 
disease were recruited. We excluded the patients with 
Diabetes Mellitus, liver disease, acute or chronic 
inflammatory disease and patient on steroid therapy. Total 
of 170 were divided into four groups as: Group I control 
subjects (GFR=116±8.3, n = 44), recruited from BBS, 
Aga Khan University. Group II, III and IV were CKD 
patients with GFR; 85.77±9.9 (n = 42), 53.84±9.9 (n = 
42) and 20.22±8.4 (n = 42), respectively were enrolled 
from Nephrology department of JPMC.  
 
Ethics statement  
The research protocol was approved by the Institutional 
Review Board of the Basic Medical Science Institute, 
Jinnah Postgraduate Medical Centre (NO.F.1-
2/2013/BMSI-E.COMT/003/ JPMC). Written informed 
consents were attained from study subjects and all 
investigations were conducted in accordance with the 
principles expressed in the Declaration of Helsinki. 
Consent for the publication of the clinical details was also 
obtained. 
 
Data collection 
At the time of enrollment questionnaire was employed to 
record the baseline demographic and clinical data of the 
study subjects from their medical records. All study 
participants were requested to come with 10-12 hours 
overnight fasting for sample collection. The analysis of 
biochemical parameters including Cholesterol, 
Triglycerides and HDL-c were measured by 
spectrophotometry using commercially available Merck 
kits. Low density lipoprotein (LDL-c) was measure by 
Friedwal’s formula (Friedewald et al., 1972). CRP 
(mg/dl) were determined by Enzyme Linked Immuno-
Sorbent Assay kit method Glomerular filtration rate 
(GFR) was estimated by Cockcroft & Gault 
equation(Cockcroft and Gault 1976). Serum leptin levels 
were measured by commercially available ELISA kits 
method. Serum HDL-cholesterol was determined by kit 
manufactured by Merck, France. LDL-cholesterol was 
calculated according to Friedewald’s formula (Friedewald 
et al., 1972). Triglycerides were determined by using 
Glycerol-3-Phosphate Oxidase Phenol Aminophenanzone 
(GPO-PAP) method, by Merck, France. Serum cholesterol 
was estimated by enzymatic colorimetric (CHOD-PAP) 
method, manufactured by Merck, France (Rifai and 
Warnick 2006) 
 
STATISTICAL ANALYSIS 
 
In this study SPSS (version 11; SPSS Inc., Chicago, IL, 
USA) was used to statistically analyze the descriptive data 
of continuous variables including age, height, weight, 
BMI and blood pressure along with serum Cholesterol, 
Triglycerides, HDL-C and LDL-c mean ± standard 
deviation (SD). Statistical comparisons were calculated 
using a student t-test and Mann Whitney U test for 
continuous/quantitative variables. Pearson’s coefficient of 
correlation (r) was used for the determination of the 
correlation of GFR levels with and lipid profile. In all 
statistical analysis performed p-values <0.05 were 
considered significant. 
 
RESULTS  
 
Total of 170 subjects had mean BMI of 22.32±0.9 
Kg/m2and mean leptin levels 8.26±4.6 ng/ml. Leptin 
levels increased significantly with progression of 
CKD.CRP was significantly increased in CDK groups as 
compared to group I (table 1). In lipid profile, cholesterol, 
triglyceride and LDL were significantly high in CKD 
groups (p<0.001), while HDL was significantly low  
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(p<0.001), as compared to Group I (table 1). The 
HDL/LDL ratio was significantly reduced with 
progression of CKD. A positive correlation was observed 
between leptin and CRP as shown in fig. 2 (r=0.994, 
p<0.001).Correlation of Leptin with HDL/LDL ratio 
showed an inverse correlation r=-0.403 with p<0.001. 
[SF2] 
Fig. 2: Correlation of Leptin and C-Reactive protein 
 
DISCUSSION 
 
There have been various studies exploring the serum 
leptin levels in different conditions but none points out it’s 
relation to metabolic dysfunction in CKD Pakistani 
population. To fill this gap we designed this study to 
assess the levels of leptin and CRP in CKD patients. 
 
Generally, high plasma concentrations of cholesterol, 
LDL, and to some extent high total triglyceride 
concentrations with low concentrations of HDL, are 
associated with increased atherosclerotic CVD risk (Kwan 
et al., 2007, Thomas et al., 2008). Same pattern of uremic 
lipid profile has been evident in our CKD population with 
gradual shift towards altered cholesterol, triglyceride and 
HDL. Various elements are concomitant with the 
development of dyslipidemia in chronic renal impairment 
(Kwan et al., 2007). 
 
Inflammation probably plays a key role in the initiation 
and progression of the atherosclerotic process(Ross 
1999). High serum concentrations of systemic 
inflammatory markers such as CRP have been associated 
with atherosclerosis (Stenvinkel et al., 2008).  
 
It has been observed that increased BMI of CKD patients 
mediate link between obesity and CVD by its effects on 
arterial pressure (Menendez et al., 2000), inflammatory 
vascular response (Konstantinides et al., 2001, Bodary et 
al., 2002), and platelet aggregation (Chaldakov et al., 
2001, Cooke and Oka 2002). Several studies advocate that 
adipose tissue releases leptin (Friedman and Halaas 1998) 
which possesses cytokine-like properties which is 
responsible for elevated IL-6 and C reactive proteins. The 
research of ours study highlight the role of Leptin in 
patients of normal BMI. Our study is strengthened by 
other studies in CKD patients where CRP was found to be 
associated with renal disease explained by the reactive 
oxygen specie being activated and causing an 
inflammatory condition. This inflammation under such 
conditions might cause altered lipid profile, thus increase 
risk for cardiovascular involvement (Briffa et al., 2013).  
 
CONCLUSION 
 
Hyperleptinemia in progressive CKD patients of our 
population demonstrated high CRP with low HDL/LDL 
ratio. This association explains the relationship of raised 
Leptin levels and CRP in progression of CKD as well as 
Table 1: Comparison of biophysical and biochemical Parameters among all groups 
 
Variable 
Group I 
(control, 
n= 44) 
Mean ± SD 
Group II 
(CKD Stage II, 
n = 42) 
Mean ± SD 
Group III 
(CKD Stage III, 
n = 42) 
Mean ± SD 
Group IV 
(CKD Stage IV, 
n = 42) 
Mean ± SD 
p value 
Age (year) 55.73 ± 2.47 54.78±2.54 55.42±3.42 57.56 ±5.49 >0.5 
Weight (kg) 58.7 ± 2.47 62.9±9.7 68.311±9.54 64.9 ± 9.7 <0.5 
Leptin (ng/ml) 2.56±1.3 6.58±1.94* 10.21±1.9°* 13.45±3.05ꜝ <0.001 
CRP (mg/dl) 2.80±0.84 3.2±0.12 3.75±0.56 4.00 ±0.76* <0.001 
Cholesterol (mg/dl) 147.4±12.28 176±5.84 198±9.24 229.86±17.65* <0.001 
Triglycerides (mg/dl) 118.5±11.66 122±9.56 169±8.65 186.7±9.19ꜝ <0.001 
HDL (mg/dl) 41.14±11.86 34.85±6.25 36.12±5.94 30.43±13.5* <0.001 
LDL (mg/dl) 80.21±13.98 101.5±16.52 145±19.23 161.1±12.95ꜝ <0.001 
HDL/LDL ratio 0.7054±0.08 0.5779±0.08 0.46±0.10 0.25±0.03 <0.001 
*significant as compared to controls, p<0.01,°significant as compared to group II, p<0.01, #significant as compared to controls and 
overweight p<0.01,ꜝsignificant as compared to group I, II, III p<0.01 
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metabolic dysregulation that may lead to pathogenesis of 
cardiovascular disease in advanced CKD patients. 
Implication of the study  
Future longitudinal studies are required to explicate the 
possible mechanisms by which leptin causes metabolic 
dys regulations in cardiovascular diseases. 
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